Divalproex Sodium Er Tablet, Extended Release
NDC Package 72189-459-60
Package Information
Divalproex Sodium Er tablets is a medication used to treat seizure disorders, mental/mood conditions (such as manic phase of bipolar disorder), and to prevent migraine headaches. This formulation utilizes a tablet, extended release delivery system. Marketed by Direct_rx, this product is identified by NDC 72189-459 and is authorized under FDA application ANDA209286.
Identification & Billing
- RxCUI: 1099569 - divalproex sodium 500 MG 24HR Extended Release Oral Tablet
- RxCUI: 1099569 - 24 HR divalproex sodium 500 MG Extended Release Oral Tablet
- RxCUI: 1099569 - divalproex sodium 500 MG 24 HR Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72189 - Direct_rx
- 72189-459 - Divalproex Sodium Er
- 72189-459-60 - 60 TABLET, EXTENDED RELEASE in 1 BOTTLE
- 72189-459 - Divalproex Sodium Er
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72189-459-60 identifies a specific commercial package of 60 tablet, extended release in 1 bottle of Divalproex Sodium Er, a human prescription drug labeled by Direct_rx. This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package. This tablet, extended release is formulated for oral use and contains divalproex sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Direct_rx on April 03, 2023. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat seizure disorders, mental/mood conditions (such as manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.
How is this Direct_rx product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72189045960. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.